CRDF Cardiff Oncology
- 4.180
- +0.010+0.24%
- 4.300
- +0.120+2.87%
Cardiff Oncology News
Cardiff Oncology Analyst Ratings
Cardiff Oncology Analyst Ratings
Cardiff Oncology (CRDF) Gets a Buy From Piper Sandler
Positive Clinical Trials and Financial Stability Propel a Buy Rating for Cardiff Oncology: An Insight Into the Anticipated Success of CRDF-004 and CRDF-005 Trials
Cardiff Oncology (CRDF) Gets a Buy From Piper Sandler
Cardiff Oncology (CRDF) Receives a Buy From TD Cowen
Cardiff Oncology's Onvansertib Shows Promise: An Analysis of the Buy Rating Recommendation
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Cardiff Oncology (CRDF) and Streamline Health Solutions (STRM)
Piper Sandler Sticks to Its Buy Rating for Cardiff Oncology (CRDF)
Cardiff Oncology (CRDF) Receives a Buy From Robert W. Baird
Cardiff Oncology Analyst Ratings
H.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)
HC Wainwright & Co. Maintains Buy on Cardiff Oncology, Lowers Price Target to $13
Cardiff Oncology Analyst Ratings
HC Wainwright Trims Cardiff Oncology Price Target to $14 From $15, Maintains Buy Rating
HC Wainwright & Co. Reiterates Buy on Cardiff Oncology, Maintains $15 Price Target
Analysts Offer Insights on Healthcare Companies: Cardiff Oncology (CRDF), Evotec AG (EVO) and Harpoon Therapeutics (HARP)
Cardiff Oncology (CRDF) Receives a Buy From Robert W. Baird
HC Wainwright Adjusts Price Target on Cardiff Oncology to $15 From $14, Keeps Buy Rating
Analysts' Top Healthcare Picks: Cardiff Oncology (CRDF), Aclaris Therapeutics (ACRS)
Analysis
Price Target
No Data
